Group 1 - Dongyangguang is planning to acquire control of Yichang Dongshu No. 1 Investment Co., Ltd. through a share issuance, leading to a stock suspension starting February 24, 2026, for up to 10 trading days [1] - Tongde Chemical has received an execution notice and ruling, resulting in the freezing and deduction of bank deposits amounting to RMB 53.93 million [2] - Palm Holdings is facing a lawsuit for a construction contract dispute with a claim amount of RMB 113 million, which represents 6.83% of the company's latest audited net assets [3] Group 2 - Duorui Pharmaceutical's tender offer period has expired, leading to a stock suspension starting February 25, 2026, after a tender offer for 19.44 million shares at RMB 32.07 per share [4] - Huazhi Media reported that the film "Silent Awakening" has grossed approximately RMB 901 million, exceeding 50% of the company's latest audited annual revenue [5] - Light Media announced that the film "Racing Life 3" has grossed about RMB 2.926 billion, also exceeding 50% of the company's latest audited annual revenue [6][7] Group 3 - Tongwei Co. is planning to acquire 100% of Lihua Qingneng Co., Ltd. through a combination of share issuance and cash payment, with a stock suspension starting February 25, 2026, for up to 10 trading days [8] - Meibang Co. confirmed that its operations are normal and there are no undisclosed significant information despite a stock price fluctuation exceeding 20% [9] - China Nuclear Construction's shareholder, China Cinda, has reduced its holdings by 8.0354 million shares, accounting for 0.2666% of the total share capital [10] Group 4 - Changxin Bochuang intends to acquire 93.81% of Shanghai Honghui Optical Communication Technology Co., Ltd. for a tentative price of RMB 375 million, aiming to enhance its capabilities in the optical communication sector [11] - Beingmei has had its patent contract dispute case accepted, with claims amounting to RMB 56.85 million, while also facing a counterclaim of RMB 77.25 million [12] Group 5 - Several companies have reported their 2025 net profit forecasts, with notable increases such as SanSheng Guojian at RMB 2.939 billion, a 317.09% increase year-on-year, while Wens Foodstuffs reported a decline of 43.59% to RMB 5.235 billion [13]

Group 1 - The company, Kewang Pharmaceutical (002737), announced that its subsidiary has received the drug registration certificate from the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution [1] - The approved indications for the drug include the treatment of chronic constipation and fecal impaction [1]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical (002737.SZ) has received a drug registration certificate from the National Medical Products Administration for its compound polyethylene glycol (3350) electrolyte oral solution, which is indicated for the treatment of chronic constipation and fecal impaction [1] Group 2 - The approved drug is aimed at addressing specific gastrointestinal conditions, highlighting the company's focus on expanding its product offerings in the pharmaceutical market [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for its product, a compound polyethylene glycol (3350) electrolyte oral solution, which is approved for the treatment of chronic constipation and fecal impaction [1] Group 1 - The product is specifically indicated for treating chronic constipation and fecal impaction [1]